Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New precision tool aims to improve liver cancer ablation

NCT ID NCT05361551

Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new, more precise way to perform liver ablation (using heat or cold to destroy tumors) in people with liver cancer. The technique combines stereotactic guidance, special CT imaging, and computer software to ensure the entire tumor is treated. About 50 participants with up to 5 small liver metastases will be enrolled to see if this approach improves treatment accuracy and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liver ablation procedure
What this could lead to
If successful, this could make liver tumor ablation more precise and effective, potentially reducing the need for repeat procedures.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The technique is complex and may not improve outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients presenting with up to 5 colorectal liver metastasis measuring up to 5 cm who are referred to percutaneous ablation; 2. Ability to completely cover the target tumor with at least a 5 mm ablation margin as determined per pre-procedure cross-sectional imaging; 3. Distance to central bile ducts \> 1 cm; 4. Adequate glomerular filtration rate (GFR \> 40) and no severe allergies to iodine contrast-media; 5. Ability to understand and the willingness to sign written informed consent; 6. Age \> 18 years-old; 7. Performance status 0-2 (Eastern Cooperative Oncology Group Classification \[ECOG\]); 8. Expected survival \> 12 months. Exclusion Criteria: 1. Use of other prior or concomitant local therapy at the target tumor(s). 2. Active bacterial infection or fungal infection on the day of the ablation. 3. Platelet \< 50,000/mm3. 4. INR \> 1.5 5. Patients with uncorrectable coagulopathy. 6. Currently breastfeeding or pregnant (latter confirmed by serum pregnancy test). 7. Physical or psychological condition which would impair study participation. 8. ASA (American Society of Anesthesiologists) score of ≥ 4. 9. Any other loco-regional therapies at the target lesion(s). 10. Anatomical variations in the arterial-hepatic blood supply of the liver that preclude the use of CTHA imaging.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic Liver ablation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.